In recent years, increasing evidence has indicated the beneficial effects of selective PI3K inhibitors on NPC, suggesting that such inhibitors may offer novel therapeutic options for the treatment of the disease. This evidence concerns the gene PIK3CA and nasopharyngeal carcinoma.